United States - English - NLM (National Library of Medicine)

team j f&b co., ltd. - silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4), alcloxa (unii: 18b8o9dqa2) (alcloxa - unii:18b8o9dqa2), aminocaproic acid (unii: u6f3787206) (aminocaproic acid - unii:u6f3787206) - purpose: anticavity uses: helps protect against cavities

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 100 mg/ml - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml excipient: nitrogen water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. localfibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). · gastrointestinal haemorrhage

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 100 mg/ml - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml excipient: nitrogen water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. localfibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). · gastrointestinal haemorrhage

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 500 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - tranexamic acid, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections - adults,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.